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● Spasticity8-19
○ Positive results seen in reduction of spasticity with medical cannabis.
○ Commonly used outcome measures were the Ashworth scale (and Modified Ashworth scale), 
Numeric Rating Scale, and Visual Analog Scale.
○ One study evaluated the combined effects of Nabiximols with PT, and found that PT was the main 
predictor of effectiveness of the Nabiximol treatment.
● Pain10,11,13,17,19,22
○ Generally positive results were seen in reduction of pain with medical cannabis.
○ Many studies used different combinations of cannabinoid extracts that authors found to be 
significant in reducing pain.
■ Nabiximols, cannabis extract of 2.5mg THC and 1.25mg CBD, THC extracts, CBD extracts, 
cigarettes with 4% THC.
● Physical Performance9,10,13,15-20
○ Results in the category of physical performance were generally indifferent.
○ Most studies used the Rivermead Mobility Index or Barthel Index and no significant differences 
were found between the cannabis and placebo group.
○ Few studies used the Ambulation Index, 10m walk test, or spatial-temporal parameters of gait; 
however, significant improvements were noted. 
● Bladder Function10,11,16,17,21,22
○ Few studies investigated the effect of medical marijuana on bladder function.
○ Some studies found subjects to perceive an improvement, but results did not reach significance.
○ The main study in this category (Kavia et al.) did not find a statistical significance in their primary 
endpoint of reduction in number of daily incontinence episodes.
● Adverse Effects (AE)8-22
○ AE were reported in all studies; however most were mild to moderate, and no serious AE were 
reported in any studies.
○ Most common AE within all studies were:
■ dizziness, headache, fatigue, confusion, blurred vision, disturbed attention, drug toxicity. 
● This systematic review provides evidence to 
support the use of medical marijuana to manage 
common MS symptoms. Strongest evidence was 
found for reductions in pain and spasticity.
● Further research is necessary to identify the extent 
of which medical marijuana is able to improve 
function and quality of life for individuals living 
with MS. 
● Multiple sclerosis (MS) is an autoimmune, 
inflammatory, demyelinating disease that is 
one of the most common neurological 
disorders in young adults, specifically ages 
20-40.1,2
● Common symptoms include pain, visual 
problems, spasticity, fatigue, impaired gait, 
and bladder dysfunction, which can impact 
overall mobility and function in daily life.3,4
● Evidence indicates that current anti-spasticity 
medications are only partially effective and 
are commonly associated with adverse effects 
including sedation, weakness and cognitive 
issues.5
● Existing literature has shown a lack of 
evidence for the effectiveness of current 
antispasticity medications used in the 
treatment of MS.
● There is growing research regarding the use 
of medical marijuana for individuals with MS 
either as an add-on therapy or monotherapy.5
● Currently in the United States, 14 states and 
the District of Columbia have legalized adult 
recreational use of marijuana, while a total of 
33 states, the District of Columbia, Guam, 
Puerto Rico, and the U.S. Virgin Islands have 
legalized the use of medical marijuana.6
● 50-90% of patients with MS would consider 
using medical marijuana if it were legal and 
more evidence was available.7
● It is imperative to explore the efficacy of 
medical marijuana as an alternative treatment 
to decrease common symptoms seen in MS.
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individuals with Multiple Sclerosis: a systematic review
● See Table 1 for databases used and number of 
articles retrieved from the search. 
● To evaluate the effectiveness of medical 
marijuana in treating common symptoms 
experienced by individuals with MS. 
● Medical marijuana may be an effective alternative 
treatment for some patients with MS, whose pain 
and spasticity are not well-managed with 
traditionally prescribed drugs. 
○ Traditionally prescribed drugs for spasticity 
include baclofen, tizanidine, dantrolene, etc. and 
side effects of these are muscle weakness, 
sedation, and fatigue.23
○ Traditionally prescribed drugs for bladder 
function include anticholinergics and side 
effects of these are dry mouth, blurred vision, 
constipation, and cognitive dysfunction.24
● Medical marijuana can also potentially improve 
gait quality and walking speed for patients with 
MS.11,20
○ Walking speed and ability are key indicators for 
disease progression in people with MS, and are 
assessed best with the Timed-25 foot walk and 
Expanded Disability Status Scale.25,26
○ Research is needed to determine whether 
medical marijuana could possibly even slow 
motor deterioration in MS and elucidate likely 
responders.
● Low to moderate AE were found overall, and are 
generally not worse than side effects seen with 
other prescribed symptomatic drugs. 
○ When researchers incorporated self-titration, 
subjects were more consistently able to achieve 
optimal dosing of medical marijuana, while 
minimizing adverse effects.9,16
● Future research is needed to examine the 
interaction of medical marijuana use and physical 
therapy intervention, in terms of both safety and 
efficacy. 
● Fifteen articles met inclusion criteria and were 
included in this systematic review. 
● Primary outcomes across the literature included 
the effect of medical marijuana on pain, fatigue, 
physical performance, sleep, cognitive function, 
spasticity, spasm frequency, spatial-temporal 
parameters of gait, ease of transfers, kinematic 
parameters within the gait cycle, timed 10 meter 
walk test, frequency of bladder incontinence 
episodes, and tremor in individuals with MS.
● After analysis of the articles, the following 
themes were identified: spasticity, pain, physical 
performance, bladder function, and adverse 
effects. 
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